10 recruiting, 5 not yet recruiting, 3 active not recruiting, 2 unknown. 7 Phase 2, 3 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 5, Active not recruiting 1, Not yet recruiting 1 |
| Not applicable | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Enrolling by invitation 1 |
Follow ctDNA: new trials by email Literature Review of ctDNA trials Research Report on ctDNA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging ctDNA-guided imaging surveillance, Standard - Triple Negative Breast Cancer, Surveillance | Not applicable | Not yet recruiting | Sunnybrook Health Sciences Centre | 30 | 2026-05-01 | 2026-03-17 |
| Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study) Blood draw for the laboratory assessment, Neoadjuvant treatment - Molecular Surveillance, Breast Cancer | Withdrawn | M.D. Anderson Cancer Center | 2026-04-09 | 2026-04-16 | ||
| Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma HLX10, SOX Chemotherapy - ctDNA, Gastric Cancer | Phase 2 | Not yet recruiting | Fudan University | 32 | 2026-04-01 | 2026-04-02 |
| ctDNA-guided Treatment Decision-making ADC, Ivonescimab - Metastatic Breast Cancer ( HER2 Negative), ctDNA | Phase 2 | Recruiting | Fudan University | 122 | 2025-12-24 | 2026-02-06 |
| Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy Step-up therapy, Standard treatment Routine treatment - Esophageal Cancer, MRD | Early Phase 1 | Enrolling by invitation | The First Affiliated Hospital with Nanjing Medical University | 65 | 2025-12-20 | 2026-01-27 |
| A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer MRD detection - Colorectal Cancer, MRD | Not yet recruiting | Sun Yat-sen University | 229 | 2025-11-24 | 2025-11-28 | |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| SMC Radiation Oncology SABR Cohort for Oligometastasis Stereotactic body radiotherapy (SBRT) - Stereotactic Body Radiation Therapy (SBRT), Oligometastasis | Recruiting | Samsung Medical Center | 60 | 2025-05-01 | 2025-08-13 | |
| A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer FOLFOX, Folfox plus Bevacizumab - ctDNA, Chemotherapy | Phase 2 | Recruiting | Fudan University | 100 | 2025-04-01 | 2026-05-01 |
| Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions Immunotherapy, Cervical Cancer | Not yet recruiting | Peking Union Medical College Hospital | 60 | 2024-12-20 | 2024-12-19 | |
| A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring Induction Immunochemotherapy - Esophageal Cancer, ctDNA | Not applicable | Recruiting | The Central Hospital of Lishui City | 30 | 2024-12-10 | 2026-03-23 |
| Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy Prostatic Neoplasms, ctDNA | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 100 | 2024-12-01 | 2024-11-27 | |
| Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - ctDNA, Chemotherapy | Phase 2 | Recruiting | Fudan University | 340 | 2024-11-01 | 2026-05-01 |
| Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer CAPEOX regimen - ctDNA, Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 340 | 2024-11-01 | 2026-05-01 |
| Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer Capecitabine - ctDNA, Colorectal Cancer (CRC) | Phase 2 | Recruiting | Fudan University | 80 | 2024-11-01 | 2026-05-01 |
| French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM) Blood sample/Liquid biopsy - Colorectal Cancer, Liver Metastases | Recruiting | University Hospital, Montpellier | 30 | 2024-04-15 | 2026-06-22 | |
| French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) Blood sample/Liquid Biopsy - Pancreatic Cancer Resectable, Pancreatic Ductal Adenocarcinoma | Recruiting | University Hospital, Montpellier | 37 | 2024-03-01 | 2025-07-10 | |
| Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description ctDNA - Gastric Cancer, ctDNA | Active not recruiting | University Medical Center Ho Chi Minh City (UMC) | 100 | 2021-10-04 | 2025-08-13 | |
| Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy NSCLC, Chemoradiotherapy | Unknown | Fudan University | 25 | 2020-04-01 | 2021-02-05 | |
| ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial ctDNA-analysis, Intensified Follow-up Schedule - Colorectal Cancer, Colo-rectal Cancer | Not applicable | Active not recruiting | Claus Lindbjerg Andersen | 359 | 2020-01-01 | 2026-04-29 |
Showing 20 of 22. Sign in to see all of them.
Colorectal Neoplasms (9) · Neoplasm, Residual (3) · Breast Neoplasms (2) · Esophageal Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Colonic Diseases (1) · Colonic Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease (1) · Gallbladder Neoplasms (1) · Gastrointestinal Neoplasms (1)
Neoplasms (20) · Neoplasms by Site (19) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Gastrointestinal Diseases (13) · Gastrointestinal Neoplasms (12) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Colonic Diseases (8) · Rectal Diseases (8) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Breast Diseases (3) · Neoplastic Processes (3) · Skin Diseases (3)
Blood Specimen Collection (3) · Capecitabine (2) · Folfox protocol (2) · Liquid Biopsy (2) · Bevacizumab (1) · Fluorouracil (1) · HMPL-013 (1) · Leucovorin (1) · Neoadjuvant Therapy (1) · Oxaliplatin (1) · Radiosurgery (1) · XELOX (1) · tislelizumab (1)
Fudan University (7) · M.D. Anderson Cancer Center (2) · University Hospital, Montpellier (2) · Claus Lindbjerg Andersen (1) · Peking Union Medical College Hospital (1) · Samsung Medical Center (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Sun Yat-sen University (1) · Sunnybrook Health Sciences Centre (1) · The Central Hospital of Lishui City (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University Medical Center Ho Chi Minh City (UMC) (1) · Yingbin Liu, MD, PhD, FACS (1)
China (12) · France (2) · Denmark (1) · South Korea (1) · United States (1) · Vietnam (1)
Arvind Dasari, MD (1) · Carlos H Barcenas, MD (1) · Claus L Andersen, PhD (1) · Huaqi Zhan (1) · Xiaojian Wu, MD, PhD (1) · Yingbin Liu, PhD (1)
PMID 25691612, PMID 33259690, PMID 33538338, PMID 35708168, PMID 36372281, PMID 36990609, PMID 38477985, PMID 40068597, PMID 40115982, PMID 40914168